Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 6:12:1022426.
doi: 10.3389/fonc.2022.1022426. eCollection 2022.

Transfusion of stored autologous blood in patients with low-grade pseudomyxoma peritonei: A retrospective analysis of its safety and outcome

Xiaoyun Gao  1 , Liduo Kou  1 , Hang Guan  1 , Hua Tian  1 , Junhui Jia  1 , Yu Bai  1 , Wei Bai  1 , Yanhui Di  1 , Ruiqing Ma  2 , Xinhua Wang  1
Affiliations

Transfusion of stored autologous blood in patients with low-grade pseudomyxoma peritonei: A retrospective analysis of its safety and outcome

Xiaoyun Gao et al. Front Oncol. .

Abstract

Background: Pseudomyxoma peritonei is a rare disease that presents as a malignant tumor on the peritoneal surface. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy is the standard treatment for this disease and frequently requires a red blood cell transfusion. However, due to the limited collection and supply of allogeneic blood, surgical treatment may be delayed due to inadequate preparation of allogeneic blood in the course of clinical treatment. This study aimed to evaluate the safety and efficacy of transfusion of stored autologous blood in patients with low-grade pseudomyxoma peritonei.

Methods: Pseudomyxoma peritonei patients who received cytoreductive surgery combined with heat-infused peritoneal chemotherapy were divided into two groups: transfusion of allogeneic blood and transfusion of stored autologous blood. A comparison of the differences in multiple factors between the two groups was performed, including tumor recurrence, survival time, hemoglobin and hematocrit levels, coagulation function (prothrombin time, activated partial thromboplastin time, and fibrinogen), total hospital stay duration, and incidence of serious adverse events after surgery.

Results: Propensity scores matching analysis yielded 34 patients with allogeneic blood transfusion and 34 patients with stored autologous blood transfusion. Comparison analysis did not show statistical differences in several factors, including age, tumor grade, tumor recurrence rate after surgery, etc., between the two groups. The cytoreductive degree was considered an independent risk factor for tumor recurrence. The pseudomyxoma peritonei patients in the autologous transfusion group had a higher 5-year survival rate and a longer survival time. Moreover, transfusion of stored autologous blood did not increase the rate of tumor recurrence, or the total hospital stay duration after surgery, the hemoglobin level and coagulation function were well stabilized within 24 h after surgery, and there was a low incidence of serious adverse events.

Conclusion: The clinical application of transfusion of stored autologous blood in pseudomyxoma peritonei patients is safe and effective.

Keywords: coagulation function; propensity score matching; pseudomyxoma peritonei; recurrence rate; stored autologous blood transfusion.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier curves of the cumulative tumor recurrence rate after the operation in the two groups.
Figure 2
Figure 2
Kaplan–Meier curves showing the overall survival of the patients in the two groups.
Figure 3
Figure 3
Distribution of serious adverse events in the two groups.
See this image and copyright information in PMC

References

    1. Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: A population based study. Eur J Surg Oncol (2008) 34(2):196–201. doi: 10.1016/j.ejso.2007.04.002 - DOI - PubMed
    1. Moran BJ, Cecil TD. The etiology, clinical presentation and management of pseudomyxoma peritonei. Surg Oncol Clin N Am (2003) 12(3):585–603. doi: 10.1016/S1055-3207(03)00026-7 - DOI - PubMed
    1. Sugarbaker PH. Pseudomyxoma peritonei. Cancer Treat Res (1996) 81:105–19. doi: 10.1007/978-1-4613-1245-1_10 - DOI - PubMed
    1. Dayal S, Taflampas P, Riss S, Chandrakumaran K, Cecil TD, Mohamed F, et al. . Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved. Dis Colon Rectum (2013) 56(12):1366–72. doi: 10.1097/DCR.0b013e3182a62b0d - DOI - PubMed
    1. Mittal R, Chandramohan A, Moran B. Pseudomyxoma peritonei: Natural history and treatment. Int J Hyperthermia (2017) 33(5):511–9. doi: 10.1080/02656736.2017.1310938 - DOI - PubMed